bioRxiv Science⌕ Search

Biology subjects

Subbarao, N.

Publications and source records attributed to Subbarao, N..

5 recordsLinked to original sources

Elucidation of putative key genes involved in the regulation of triple negative breast cancer development and progression

The molecular basis of triple-negative breast cancer (TNBC), a highly aggressive and therapy-resistant subtype of breast cancer, is poorly understood. This study aims to identify key genes and pathways involved in TNBC development and progression using a systems biology approach followed by experimental validation. Here, two transcriptome microarray datasets from the GEO database were analysed using the R package LIMMA to detect differentially expressed genes (DEGs) in TNBC tumors. Gene Ontology (GO) and Kyoto Encyclopaedia of Genes and Genomes (KEGG) enrichment analyses using the DAVID database were performed to identify DEGs regulated biological functions and pathways. Further, a protein-protein interaction (PPI) network was constructed using the STRING online database, and the topological properties were determined using MCODE and Cytohubba plug-ins. The expression and the prognostic value of the hub genes were validated using the Cancer Genome Atlas (TCGA) survival analysis. We found 727 DEGs, of which 473 were downregulated and 254 were upregulated in TNBC vs. non-TNBC samples. The GO and KEGG analyses indicated that the DEGs were mainly related to cell adhesion, tumorigenesis, and cellular immunity. The PPI network had shown six hub genes, namely CCND1, CDH1, ESR1, FN1, IL6, and PPARG, as the top key regulators. All these genes were validated by quantitative real-time PCR in the TNBC cell line using non-TNBC cell line as a calibrator, and the obtained results were in accordance with the bioinformatics data. This information may contribute to understanding the various molecular mechanisms that drive the development and progression of TNBC tumors.

cancer biology↗

Transcriptome-based lead generation, ligand- and structure-based prioritization and experimental validation of TLR5-activating molecules

Current in silico drug discovery protocols ubiquitously depend on lead generation using a ligand-based approach in which novel leads are generated by fragment-signature matching or by a structure-based search involving molecular docking and conformational dynamics. None of them incorporates cellular contexts in which these drugs ultimately operate, leaving the task to a later stage of optimization leading to a high failure rate. Incorporating systems-level responses of drugs in an early stage of lead generation can significantly address this concern but has not been sufficiently explored. In this work, we employ a systems-level approach using connectivity map (CMAP) library to generate leads against a challenging system of a TLR pathway. Starting with gene expression data of TLR5 activation by its natural ligand, we generated molecular leads using CMAP and rigorously analyzed their validity using ligand and structure-based approaches, and helping to prioritize top hits. Experimental validation using ELISA-based antibody assay confirmed the activation of TLR5 by each of the top nine prioritized leads with their dose-dependent patterns suggesting that some of them may actually interact with the TLR signaling pathway in a complex manner. Although, demonstrated on TLR5, the proposed framework is intuitively scalable to other lead generation and optimization tasks.

bioinformatics↗

Structural insight into antibody evasion of SARS-CoV-2 omicron variant

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to mutate and evolve with the emergence of omicron (B.1.1.529) as the new variant of concern. The rapid spread of this variant regionally and globally could be an allusion to increased infectivity, transmissibility, and antibody resistance. The omicron variant has a large set of mutations in its spike protein, specifically in the receptor binding domain (RBD), reflecting their significance in ACE2 interaction and antibody recognition. We have carried out the present study to understand how these mutations structurally impact the binding of the antibodies to their target epitope. We have computationally evaluated the binding of different classes of RBD targeted antibodies, namely, CB6 (etesevimab), REGN10933 (casirivimab), S309 (sotrovimab), and S2X259 to the omicron mutation-induced RBD. Molecular dynamics simulations and binding free energy calculations unveil the binding affinity and stability of the antibody-RBD complexes. All the four antibodies show reduced binding affinity towards the omicron RBD. The therapeutic antibody CB6 aka etesevimab was substantially affected due to numerous omicron mutations occurring in its target epitope. This study provides a structural insight into the reduced efficacy of RBD targeting antibodies against the SARS-CoV-2 omicron variant.

bioinformatics↗

Novel inhibitors designing against the potential drug target of Plasmodium falciparum M17 Leucyl Aminopeptidase - PfM17LAP

Malaria is one of the major disease of concern worldwide especially in the African regions. According to the recent WHO reports, African regions share 95% of the total deaths worldwide that occurs due to malaria. Plasmodium falciparum M17 Leucyl Aminopeptidase (PfM17LAP) plays an important role in the regulation of amino acids release and for the survival of the parasite. We performed molecular docking and simulation studies to find the potential inhibitors against PfM17LAP using ChEMBL antimalarial library. Molecular docking studies and post-docking analysis revealed that molecules CHEMBL369831 and CHEMBL176888 showed better binding than the reference molecule BESTATIN. LibDock and X-SCORES of molecules BES, CHEMBL369831 and CHEMBL176888 are 130.071, 230.38, 223.56 and -8.75 Kcal/mol, -10.90 Kcal/mol, -11.05 Kcal/mol respectively. ADMET profiling of the top ten ranked molecules was done by using the Discovery Studio. Molecular dynamic studies revealed that the complex PfM17LAP-CHEMBL369831 is stable throughout the simulation. Finally, we have reported novel inhibitors which possess more binding affinity towards PfM17LAP.

bioinformatics↗

Predicting JNK1 Inhibitors Regulating Autophagy in Cancer using Random Forest Classifier

Autophagy (in Greek: self-eating) is the cellular process for delivery of heterogenic intracellular material to lysosomal digestion. Protein kinases are integral to the autophagy process, and when dysregulated or mutated cause several human diseases. Atg1, the first autophagy-related protein identified is a serine/threonine protein kinases (STPKs). mTOR (mammalian Target of Rapamycin), AMPK (AMP-activated protein kinase), Akt, MAPK (mitogen-activated protein kinase) and PKC (protein kinase C) are other STPKs which regulate various components/steps of autophagy, and are often deregulated in cancer. MAPK have three subfamilies - ERKs, p38, and JNKs. JNKs (c-Jun N-terminal Kinases) have three isoforms in mammals - JNK1, JNK2, and JNK3, each with distinct cellular locations and functions. JNK1 plays role in starvation induced activation of autophagy, and the context-specific role of autophagy in tumorigenesis establish JNK1 a challenging anticancer drug target. Since JNKs are closely related to other members of MAPK family (p38, MAP kinase and the ERKs), it is difficult to design JNK-selective inhibitors. Designing JNK isoform-selective inhibitors are even more challenging as the ATP-binding sites among all JNKs are highly conserved. Although limited informations are available to explore computational approaches to predict JNK1 inhibitors, it seems diificult to find literature exploring machine learning techniques to predict JNKs inhibitors. This study aims to apply machine learning to predict JNK1 inhibitors regulating autophagy in cancer using Random Forest (RF). Here, RF algorithm is used for two purposes- to select and rank the molecular descriptors calculated using PaDEL descriptor software and as clasifier. The descriptors are prioritized by calculating Variable Importance Measures (VIMs) using functions based on mean square error (IncMSE) and node purity (IncNodePurity) of RF. The classification models based on a set of 22 prioritized descriptors shows accuracy 86.36%, precision 88.27% and AUC (Area Under ROC curve) 0.8914. We conclude that machine learning-based compound classification using Random Forest is one of the ligand-based approach that can be opted for virtual screening of large compound library of JNK1 bioactives.\n\nAuthor SummaryOut of the three isoforms of JNKs (cJun N-terminal Kinases) in human (each with distinct cellular locations and functions), JNK1 plays role in starvation induced activation of autophagy. The role of JNK1 in autophagy modulation and dual role of autophagy in tumor cells makes JNK1 a promising anticancer drug target. Since JNKs are closely related to other members of MAPK (Mitogen-Activated Protein Kinases) family, it is difficult to design JNK selective inhibitors. Designing JNK isoformselective inhibitors are even more challenging as the ATP binding sites among all JNKs are highly conserved. Random forest classifier usually outperforms several other machine learning algorithms for classification and prediction tasks in diverse areas of research. In this work, we have used Random Forest algorithm for two purposes: (i) calculating variable importance measures to rank and select molecular features, and (ii) predicting JNK1 inhibitors regulating autophagy in cancer. We have used paDEL calculated molecular features of JNK1 bioactivity dataset from ChEMBL database to build classification models using random forest classifier. Our results show that by optimally selecting features from top 10% based on variable importance measure the classification accuracy is high, and the classification model proposed in this study can be integrated with drug design pipeline to virtually screen compound libraries for predicting JNK1 inhibitors.

bioinformatics↗